▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

I-Mab (NASDAQ: IMAB)

$1.18

(13.5%)

$0.14

Price as of May 28, 2025, 3:58 p.m. ET

I-Mab Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
IMAB	-32.76%	-95.31%	-45.76%	-91%
S&P	+11.63%	+95.45%	+14.34%	+77%

I-Mab Company Info

I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company was founded by Jingwu Zang on June 30, 2016 and is headquartered in Pudong, China.

News & Analysis

Featured Article

AbbVie Partners With I-Mab for Cancer Drug

The deal could be the largest-ever out-licensing agreement by a Chinese biotech.

Jim Crumly | Sep 4, 2020

Valuation

Earnings Transcripts

I-MAB (IMAB) Q2 2021 Earnings Call Transcript

IMAB earnings call for the period ending June 30, 2021.

Motley Fool Transcribers | Aug 31, 2021

IMab ADR (IMAB) Q4 2020 Earnings Call Transcript

IMAB earnings call for the period ending December 31, 2020.

Motley Fool Transcribers | Mar 29, 2021

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services